anti-CD276-UAA-PBD ADC / BrickBio - LARVOL DELTA

BrickBio Achieves Unprecedented Breakthrough in Cancer Therapy with Novel ADC: 5X Increase in Therapeutic Window for Potent Payload with Complete Tumor Eradication (PRNewswire) - "BrickBio.com...proudly announces a groundbreaking achievement that has the potential to revolutionize cancer treatment. For the first time, BrickBio has achieved a remarkable 5X increase in the therapeutic window for PBD (Pyrrolobenzodiazepine) over what has been previously achieved with the payload, leading to complete eradication of tumors in animal models. The company is now gearing up for advanced studies targeting CD276 (B7-H3), utilizing its novel antibody. This revolutionary antibody, exclusively licensed from a third party and extensively published, has demonstrated unprecedented efficacy in preclinical models, showcasing its potential to redefine cancer therapy....The company is now poised to advance to further Non-Human Primate (NHP) studies and Investigational New Drug (IND) -enabling studies against B7-H3."

Preclinical • Oncology